Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine in previously treated acute myeloid leukemia
NCT02920008Phase 3Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 15
01
Overview
A Phase 3 trial of guadecitabine in acute myeloid leukemia (AML), sponsored by Astex Pharmaceuticals. Started Mar 2017; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02920008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920008.